Mice deficient in pyruvate dehydrogenase kinase 4 are protected against acetaminophen-induced hepatotoxicity.


Journal

Toxicology and applied pharmacology
ISSN: 1096-0333
Titre abrégé: Toxicol Appl Pharmacol
Pays: United States
ID NLM: 0416575

Informations de publication

Date de publication:
15 01 2020
Historique:
received: 23 08 2019
revised: 22 11 2019
accepted: 02 12 2019
pubmed: 7 12 2019
medline: 22 8 2020
entrez: 7 12 2019
Statut: ppublish

Résumé

Though mitochondrial oxidant stress plays a critical role in the progression of acetaminophen (APAP) overdose-induced liver damage, the influence of mitochondrial bioenergetics on this is not well characterized. This is important, since lifestyle and diet alter hepatic mitochondrial bioenergetics and an understanding of its effects on APAP-induced liver injury is clinically relevant. Pyruvate dehydrogenase (PDH) is critical to mitochondrial bioenergetics, since it controls the rate of generation of reducing equivalents driving respiration, and pyruvate dehydrogenase kinase 4 (PDK4) regulates (inhibits) PDH by phosphorylation. We examined APAP-induced liver injury in PDK4-deficient (PDK4

Identifiants

pubmed: 31809757
pii: S0041-008X(19)30457-0
doi: 10.1016/j.taap.2019.114849
pmc: PMC6995777
mid: NIHMS1546522
pii:
doi:

Substances chimiques

Pdk4 protein, mouse 0
Pyruvate Dehydrogenase Acetyl-Transferring Kinase 0
Ucp2 protein, mouse 0
Uncoupling Protein 2 0
Acetaminophen 362O9ITL9D

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

114849

Subventions

Organisme : NIGMS NIH HHS
ID : P30 GM118247
Pays : United States
Organisme : NIDDK NIH HHS
ID : F31 DK120194
Pays : United States
Organisme : NIGMS NIH HHS
ID : P20 GM103549
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK102142
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK119131
Pays : United States

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

Toxicol Appl Pharmacol. 2012 Nov 1;264(3):387-94
pubmed: 22980195
J Biol Chem. 2008 May 16;283(20):13565-77
pubmed: 18337250
Hepatology. 2016 Jun;63(6):1987-2003
pubmed: 26845758
Redox Biol. 2016 Dec;10:148-156
pubmed: 27744120
Arch Toxicol. 2017 Feb;91(2):761-773
pubmed: 27002509
Hepatology. 2012 Jul;56(1):281-90
pubmed: 22318764
PLoS Genet. 2014 Jun 19;10(6):e1004385
pubmed: 24945157
J Pharmacol Exp Ther. 1999 Apr;289(1):580-6
pubmed: 10087053
Toxicol Appl Pharmacol. 2002 Jun 1;181(2):106-15
pubmed: 12051994
Biochim Biophys Acta. 2006 May-Jun;1757(5-6):480-5
pubmed: 16597432
Toxicol Sci. 2011 Aug;122(2):598-605
pubmed: 21572097
Hepatology. 2010 Jan;51(1):246-54
pubmed: 19821517
J Pharmacol Exp Ther. 2012 Sep;342(3):676-87
pubmed: 22647274
FEBS Lett. 2007 Feb 6;581(3):479-82
pubmed: 17240372
J Biol Chem. 2011 Oct 7;286(40):35071-8
pubmed: 21844199
Toxicol Appl Pharmacol. 2011 Mar 15;251(3):226-33
pubmed: 21241727
Pharm Res. 2013 Sep;30(9):2174-87
pubmed: 23462933
Biochem Biophys Res Commun. 2018 Jan 1;495(1):582-586
pubmed: 29128353
Diabetes. 2018 Oct;67(10):2054-2068
pubmed: 30065033
Toxicol Pathol. 2009 Feb;37(2):193-200
pubmed: 19332662
Toxicol Appl Pharmacol. 2010 Jul;246(1-2):8-17
pubmed: 20423716
Drug Metab Dispos. 2002 Apr;30(4):446-51
pubmed: 11901099
BMC Med Genomics. 2018 Dec 14;11(1):111
pubmed: 30547786
Mol Cancer Ther. 2019 Oct;18(10):1673-1681
pubmed: 31511353
Toxicol Sci. 2004 Aug;80(2):343-9
pubmed: 15115886
J Neurochem. 2007 Jun;101(6):1619-31
pubmed: 17437552
Adv Pharmacol. 2019;85:75-107
pubmed: 31307592
J Immunol. 2011 Aug 1;187(3):1322-32
pubmed: 21705615
J Pharmacol Exp Ther. 2002 Nov;303(2):468-75
pubmed: 12388625
Semin Liver Dis. 2019 May;39(2):221-234
pubmed: 30849782
J Biochem Mol Biol. 2006 Sep 30;39(5):479-91
pubmed: 17002867
Hepatology. 2018 Sep;68(3):1111-1124
pubmed: 29603325
Toxicol Appl Pharmacol. 2014 Nov 15;281(1):58-66
pubmed: 25218290
Toxicol Appl Pharmacol. 2010 Jan 15;242(2):182-90
pubmed: 19835899
Semin Respir Crit Care Med. 2012 Feb;33(1):36-45
pubmed: 22447259
Liver Int. 2014 Aug;34(7):e171-9
pubmed: 24575957
Am J Physiol Endocrinol Metab. 2008 Jul;295(1):E46-54
pubmed: 18430968
Toxicol Sci. 2006 Nov;94(1):217-25
pubmed: 16896059
Arch Physiol Biochem. 2006 Jul;112(3):139-49
pubmed: 17132539
Biochem J. 2006 Aug 1;397(3):417-25
pubmed: 16606348
Methods Enzymol. 1990;186:752-9
pubmed: 2233332
Toxicol Sci. 2002 Jun;67(2):322-8
pubmed: 12011492
Nutr Metab (Lond). 2014 Feb 12;11(1):10
pubmed: 24520982
Arch Toxicol. 2019 Jan;93(1):163-178
pubmed: 30324313
J Pharmacol Exp Ther. 2005 Nov;315(2):879-87
pubmed: 16081675
J Cell Sci. 2010 Feb 15;123(Pt 4):578-85
pubmed: 20103532

Auteurs

Luqi Duan (L)

Department of Pharmacology, Toxicology & Therapeutics and Department of Urology, University of Kansas Medical Center, Kansas City, KS, USA.

Anup Ramachandran (A)

Department of Pharmacology, Toxicology & Therapeutics and Department of Urology, University of Kansas Medical Center, Kansas City, KS, USA.

Jephte Y Akakpo (JY)

Department of Pharmacology, Toxicology & Therapeutics and Department of Urology, University of Kansas Medical Center, Kansas City, KS, USA.

Benjamin L Woolbright (BL)

Department of Pharmacology, Toxicology & Therapeutics and Department of Urology, University of Kansas Medical Center, Kansas City, KS, USA.

Yuxia Zhang (Y)

Department of Pharmacology, Toxicology & Therapeutics and Department of Urology, University of Kansas Medical Center, Kansas City, KS, USA.

Hartmut Jaeschke (H)

Department of Pharmacology, Toxicology & Therapeutics and Department of Urology, University of Kansas Medical Center, Kansas City, KS, USA. Electronic address: hjaeschke@kumc.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH